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SUMMARY 
Chronic hepatitis C Virus (HCV) is the leading cause of liver cirrhosis worldwide and in 
Egypt. Patients with cirrhosis secondary to chronic HCV infection are at increased risk 
for developing Hepatocellular carcinoma (HCC) in which Interferon therapy is the only 
effective anti-viral therapy. The current study aimed to investigate the expression IFN-α 
and IFN-α Receptor genes in liver biopsies from patients with HCV and HCC. 
Correlation of their expression with the clinical, histopathological progress of the disease 
and the effectiveness of IFN therapy in HCV patients after a period of 6 months follow-
up was done. Expression of IFN-α and IFNα-Rc m-RNA was investigated by RT-PCR 
using liver biopsy specimens from 30 HCV patients including 7 patients complicated 
with HCC. Liver biopsies were also subjected to formalin fixation for complete 
histopathological examination.  Ninety seven percent of patients expressed Interferon 
Alpha m-RNA while 30% only expressed Interferon Alpha Receptor m-RNA. 
Responders and non-responders to Interferon therapy were divided according to their 
HCV RNA after six-months follow up period of interferon therapy. Responders showed 
significantly lower mean age, better histopathological states and higher incidence of 
expression of IFN Alpha Receptor mRNA. Regardless of the response to interferon, 
histological activity index scores and the degree of fibrosis showed a significant inverse 
correlation to the presence of IFNα-R m-RNA. IFNα-R mRNA expression decreases with 
the histological progress of the disease, suggesting that lower expression of the IFNα-Rc 
may be partially responsible for the unfavorable response to interferon in these patients.
[Afr J Health Sci. 2007; 14:86-96] 
 
Introduction 
Interferon therapy is the only strategy at present 
potentially capable of eliminating HCV from 
hepatocytes [1]. However less than half of 
Egyptian HCV patients are able to eliminate HCV 
RNA from their serum with IFN therapy and most 
relapse after cessation of therapy [2].  Persistent 
HCV infection is a major risk factor for the 
development of HCC. Approximately 80% of 
Japanese HCC patients are also diagnosed with 
HCV-associated cirrhosis or chronic hepatitis C. It 
has also been shown that the risk of HCC increases 
with the degree of liver fibrosis [1]. HCV-related 
end-stage liver disease is now the principal 
indication for liver transplantation in Egypt [3]. 
Almost all viruses, however, have evolved 
mechanisms to evade the interferon system by 
partially blocking interferon synthesis or interferon 
action. Viral evasion mechanisms include block of 
interferon synthesis, blocking of interferon 
signaling, and blocking of the function of IFN-
induced proteins [4]. IFN treatment is expensive 




response to IFN is especially meaningful for 
patients with HC and HCC [5]. However, the 
determination of IFN responsiveness is 
complicated and several factors may influence it. 
HCV titre and genotype, heterogeneity of the virus 
(mutations in NS5A proteins) and interferon 
sensitivity determining region of the viral genome 
(ISDR) are all viral related factors [6-8]. Host 
factors also influence the responsiveness, including 
younger age, female sex, low pretreatment HCV 
RNA level, absence of fibrosis or cirrhosis, higher 
or longer doses of IFN, and non-type 1b viral 
genotype have been associated with an increased 
response to IFN-α therapy [9]. IFN-  acts on target 
cells to confer a state of resistance to viral 
infectivity at one or more stages of virus entry or 
replication. These biological effects require binding 
to the type I IFN receptor complex, which is 
composed of two subunits,  and  [10]. Synthesis 
of Interferon is induced by activating the Jak-Stat 
pathways of cell signaling. The signaling is 
initiated through the binding of these protein 
kinases to the Interferon receptors, Type 1 and 
Type II. IFN-α and IFN-β have a common receptor 
 




(Type 1) while IFN-γ has its own receptor (Type 
II). These are essential steps to establish the anti-
viral state where response to Interferon in chronic 
hepatitis C depends on the IFN-Receptor 
expression [11]. 
In the present study, the expression of IFNα 
mRNA together with IFNα-Rc typeI mRNA was 
examined in patients with HCV associated chronic 
liver disease (CLD) using liver biopsy specimens to 
investigate whether differences in expression of 
IFNα  & INFα-Rc may be associated with the 
biochemical, virological and histological progress 
of HCV-associated CLD. 
Materials and Methods 
Patients 
Thirty patients with HCV associated CLD (7 
patients had hepatocellular carcinoma [HCC]) 
participated in the present study. They comprised 
12 females and 18 males aged from 29-61 years 
(mean±SD 45.7±8.6). All patients were followed 
up at KASR ELAINI Hospital Cairo University 
during the years 2001-2004. Patients were assessed 
prior to treatment by complete liver function tests, 
abdominal U/S, hepatitis markers and AFP on the 
Axsym (Abbott Laboratories USA). ANA and 
antibilharzial antibodies were done to exclude other 
complications. Finally serum HCV-RNA was 
extracted and analysed by the nested RT-PCR. 
HCV genotyping was done to confirm the 
diagnosis of HCV infection [12].  
Liver biopsy was performed in all cases with a 
Trucut Biopsy Needle to decide the indication of 
IFNα therapy [13]. Liver biopsy specimens were 
divided into two parts immediately after biopsy. 
Half of the specimen was immersed in formalin for 
fixation and histological examination. The other 
half was immersed in HANK’s solution for RNA 
extraction and IFN assessment. Informed consent 
was obtained from all patients and their relatives 
prior to biopsy. 
 
Selection of patients for therapy 
Patients were recommended for INFα therapy when 
they had their liver enzymes elevated at least 1.5 
times the upper limit of normal for six months, 
positive HCV-RNA and liver histology with at 
least moderate degree of necroinflammatory 
changes [2]. Twenty-three out of the 30 patients 
who were suffering from HCV only without HCC 
received Interferon therapy and ribavarin while the 
other seven patients received special therapy for 
HCC including IFN. 
 
Therapy protocol 
The patients were treated with Regular Interferon 
(either Interferon Alpha 2a (Roferon-Roche, 
Switzerland) or Interferon Alpha 2b (Interon- 
Scherring, USA) and Ribavarin. An injection of 3 
million units was administered 3 times per week 
for 24 weeks (6 months). Ribavarin was 
administered according to body weight (10.5 
mg/kg/day) with the average dose ranging from 
800 to 1000 mg/day [2].  
 
Follow-up protocol 
The twenty-three patients who were HCV positive 
without HCC were followed up for interferon 
response. Response to interferon therapy was 
assessed after six months of therapy initiation. 
Biochemical and virological response to IFN were 
assessed at the end of the treatment period (primary 
response), at week 24, and at the end of the follow 
up period, week 48. Biochemical response was 
defined as serum ALT concentrations within 
normal ranges and a virological response as the 
absence of serum HCV RNA by RT-PCR. Serum 
HCV RNA was confirmed by real time PCR [7,14]  
Nested RT-PCR 
RNA extraction and reverse transcription  
Total RNA was extracted from the serum of 
patients prior to treatment by acid guanidium 
phenolchloroform (AGPC) method. Reverse 
transcription was performed with 0.5 µL of 15 
U/µL AMV reverse transcriptase (Amersham, 
Braunschweig, Germany), 4 µL RT buffer (250 
mmol/L Tris-HCl [pH 8.3], 40 mmol/L MgCl2, 
250 mmol/L NaCl, 5 mmol/L dithiothreitol), 4 µL 
of 1 mmol/L dNTPs, 0.2 µL RNase inhibitor, 1 µL 
of 10 µmol/L outer antisense primer, and 2.5 µL of 
the extracted RNA in a total volume of 20 µL at 
42°C for 1 hour.  
Oligonucleotide primers  
Nested RT-PCR was performed with the following 
primers corresponding to the highly conserved 
genomic sequence of the 5´-noncoding region 
(NCR) of HCV, 5´-
CTGTGAGGAACTACTGTCTT-3´ (position 45-
64, outer sense12),  
5´-AACACTACTCGGCTAGCAGT-3´ (position 
246-265, outer antisense),  
5´-TTCACGCAGAAAGCGTCTAG-3´ (position 
63-82, inner sense12),  
5´-GTTGATCCAAGAAAGGACCC-3´ (position 
188-207, inner antisense). 
The resulting length of amplification products was 
206 bp and 115 bp, respectively [15]. 
 
Nested PCR  
Nested PCR was performed with 0.2 µL of 5 U/µL 
Taq DNA-polymerase (Boehringer Mannheim, 
Mannheim, Germany) in the presence of 5 µL of 1 
mmol/L dNTPs, 5 µL PCR buffer (100 mmol/L 
Tris-HCl, 15 mmol/L MgCl2, 500 mmol/L KCl 
[pH 8.3]), 0.5 µL of each sense and antisense 
primer (10 µmol/L), and 5 µL of cDNA in a total 
volume of 50 µL. Five microliters of product of the 
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first PCR diluted 1:100 was added for the second 
PCR. The number of cycles was 35 for each PCR, 
with an annealing temperature of 56°C and 60°C, 
respectively. Nine microliters of PCR product was 




HCV genotyping was carried out with a second 
generation reverse hybridisation, line probe assay 
(Inno-LiPA HCV II; Innogenetics, Ghent, 
Belgium) according to the manufacturer's 
instructions with the amplified product of the 
nested PCR [11 ,12]. 
 
Histological studies 
Biopsy specimens were fixed in 4% neutral 
buffered formaldehyde and embedded in paraffin. 
Biopsy specimens were stained with haematoxylin 
and eosin. Two other stainings (eosin Sirius red, 
Masson’s trichrome) were used for fibrosis staging. 
Biopsy specimens obtained were assessed for 
fibrosis (score 0–6) and histological activity index 
(HAI score 0–18) according to the scoring systems 
of Desmet et al and Ishak et al respectively [16,17]. 
A diagnosis of recurrent hepatitis was based on the 
presence of portal, periportal, and lobular 
inflammation, with lobular acidophilic bodies 
and/or lobular hepatocytolysis, all in the absence of 
endothelitis. 
 
RNA extraction and preparation of c-DNA 
from liver biopsy 
Small parts of each biopsy specimen were 
immediately frozen in liquid nitrogen for disruption 
and homogenization. Disruption was performed 
using a mortar and pestle and ground into a fine 
powder. The liquid nitrogen was allowed to 
evaporate but the sample was not allowed to thaw. 
Homogenization was necessary to reduce the 
viscosity of the cell lysates produced by the 
disruption by adding RLT Buffer. The lysate was 
pipetted into the QIAshredder spin column and 
total RNA was extracted using Quiagen RNA 
Extraction Kit (Quiagen Catalogue # 52304, USA) 
from tissue biopsies according to the 
manufacturer's guide. 10 ul of total RNA were 
transcribed to c-DNA using random hexamers 
primers for RT-PCR. The procedure of RT was the 
same as described before [17, 18].  
 
Determination of IFNα and IFNα-Receptor 
gene expression 
Complementary DNA (c-DNA) was used as a 
template for the PCR. The sequence of the primers 
were;  
IFN-α Sense: 5’ ACC TCC TGC ATC ATA CAG 
GC 3’,  
IFN-α AntiSense: 5’ CAG TTC CAG AAG GCT 
CAA GC 3’  
IFN-α Receptor Sense: 5’-AGT GTT ATG TGG 
GCT TTG GAT GGT TTA AGC-3’  
IFN-α Receptor AntiSense:5’TCT GGC TTT CAC 
ACA ATA TAC AGT CAG TGG-3’.  
Β-actin sense: 5'ATC TGG CAC CAC ACC TCC 
TAC AAT GAG CTG CG-3'  
Β-actin antisense: 5'CGT CAT ACT CCT GCT 
TGC TGA TCC ACA TCT GC3'.   
All primers were obtained from Prof Dr. Nader 
Abraham (director of gene therapy, Pharmacology 
department New York Medical College, Valhalla 
NY. 10509). Optimal PCR conditions were as 
follows; Denaturation Step: 95°C for 5 minutes (1 
cycle), Amplification Step: 95°C for 1 minute, 
55°C for 1 minute, 72°C for 2 minutes, this was 
repeated for 40 cycles, Final Extension: 72°C for 
15 minutes. For each sample, individual detection 
of INFα mRNA and INFα-Rc mRNA was 
performed separately using specific primers for 
each of them and the same PCR conditions were 
followed for both. The amplified products were 
loaded with a loading buffer (bromophenol blue) 
run on 2% agarose gel. A visualized DNA band at 
the length 303bp was considered positive for IFN-
alpha and at 765bp was considered positive for 
IFN-Rc and at 838bp for β-actin [17, 18]. The size 
of the amplified product was read by the aid of a 
DNA marker.  
 
HCV by real time PCR 
At the end of the 24 weeks of treatment and after 6 
months, HCV RNA was checked in the serum of 
the 23 patients using Real time PCR.The majority 
of samples were extracted with the Roche MagNA 
Pure LC instrument with the MagNA Pure LC total 
nucleic acid isolation kit, according to the 
manufacturer’s instructions.  
          HCV assay. Twenty microliters of RNA was 
added to 30µl of master mix for the HCV 
amplification and detection reaction. The Mn 
concentration was 3 mM. Each of the three 5' 
primers was at a final concentration of 360 nM, and 
the probes were each at 80 nM. A mixture of four 
different primers and two probes were used to 
amplify a region of the 5'untranslated region 
(5'UTR) of HCV. The sequence of the primers 
were GCGACACTCCACCATAGATCACT3, 
CGACACTCCACCATGAATCACT3  and  
CACTCCGCCATGAAYCACT (where Y is C or 
T). The 3' primer was 
CACTCGCAAGCACCCTATCA. The probes 
were 6-carboxyfluorescein–
AGGCCTTTCGCGACCCAACACTACTC–
tetramethyl carboxyrhodamine (TAMRA) and 6-
carboxyfluorescein–
AGGCCTTTCGCAACCCAACGCTACT–
tetramethyl carboxyrhodamine.[19]17  
 




The amplification reaction was carried out in an 
ABI 7700 instrument with the following cycles: 
50°C for 2 min, 60°C for 30 min, 95°C for 2 min, 
then repeat cycling of 95°C for 15 s and then 60°C 
for 1 min for a total of 45 cycles. Analysis was 
performed with the ABI SDS software and an 
imported ready-made standard curve was used for 
quantification of the samples. At the end of each 
run, a DNA melting step was performed, and the 
fusion curve was recorded to control for the 
homogeneity and quality of amplified DNA [11].  
Statistical analysis 
Individual data was summarized and presented in 
the form of range, mean and standard deviation as 
descriptive statistics. Statistical analysis was 
performed using the statistical software program 
SPSS (version 10). Two tests were performed. Chi 
Square test for statistical significance for 
determinations of associations between rows and 
columns was performed and Mann Whitney Non-
parametric test was performed to compare means. 
P-value of less than 0.05 was considered 
significant. 
 
Results                  Fig 1: IFN Alpha mRNA Bands in Agarose Gel 
                                              Lane No.   1     2     3    4     5     6    7    8     9     10 
 
                                                                              Fig 2: IFN Alpha Receptor mRNA Bands in Agarose Gel 
                                                                               Lane No.   1    2     3    4    5    6   7    8     9    10 
 
                      
Lane 1,2,3,8,9:  
Positive for IFN Alpha Receptor 
Lane 4,5,6, 7: 
 Negative for IFN Alpha Receptor   
Lane 10: 
Showing molecular weight marker 
of the following base pairs 
respectively: 50 bp, 150 bp, 350 bp, 
500 bp, 750 bp and 1000 bp 
(Promega 3161)  
 :,9,8,7,5,4,3,21Lane 
Positive for IFNα-gene 
: 6Lane  
Negative for IFNα-gene 
: 10Lane   
Showing molecular weight 
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                           Fig 3: HCV Real- time PCR results imported on a standard curve 
 
 
Clinical and laboratory data of patients 
before treatment 
All patients had elevated liver functions of at least 
1.5 fold the upper limit of the normal, elevated 
AFP levels and were positive for the anti-HCV 
antibody. No cases showed markers for the HBV 
including, HBsAg, HBeAg/Ab, HbcAb nor 
antinuclear antibodies. Antibilharzial antibodies 
were below the significant limit (1/160) in all 
patients. Serum HCV RNA was positive in all 
patients. Seven patients had hepatic focal lesions 
and all revealed to be malignant i.e. they had HCC 
on top. HCC patients had a statistically significant 
higher mean age together with higher total and 
direct bilirubin and AFP levels (P-values <0.001 in 
all), however no statistical differences were 
observed regarding the rest of the liver enzymes 











after IFN therapy as they had a different 
therapeutic protocol. All patients had HCV 
genotype 4 however the subtypes were 
undetermined by the reverse hybridization, line 
probe assay and needed to be sequenced for 
determination. 
 
IFN-α and IFN-α Receptor mRNA 
expression in the liver 
All the patients showed IFN-α gene expression 
except one patient who had the highest degree of 
fibrosis (fibrosis grade 5) and HAI Index of 9. IFN-
α Receptor mRNA was expressed in 30% (9/30) 
(Figure 4). Non of the patients with HCC had 
IFNα-Rc expression and the difference was 
statistically significant P=0.047. (Table 1). Patients 
with IFN-α Receptor mRNA expression had a 
younger mean age (P=0.01) compared to those who 
had no expression, while there was no other 
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 Table1: IFN Alpha Receptor mRNA expression in the study group  
 IFNα-Rc Positive IFNα-Rc Negative P-Value Significance 
Total Number 9 21 
HCV Positive (23) 9/30 (30%) 14/30 (46.7%) 
HCV Positive & HCC (7) 0/30 (0%) 7/30 (23.3%) 
0.047 Significant 
 
 Fig 4: Percentage of IFN-α Receptor expression in the study groups 
30%
0%
0% 5% 10% 15% 20% 25% 30%




Relationship between histological activity and 
IFNα-Rc mRNA  
Necroinflammatory activity, represented by the 
sum of the histological activity index (HAI) scores 




with the expression of IFN Alpha Receptor m-RNA 
(P= 0.0034 and 0.007 respectively) Fig 5&6. The 
higher the score, the higher the degree of 
inflammation and fibrosis.  
 































levels of f ibrosis
IFN Receptor Negativ e 0 0 1 1 4 8
IFN Receptor Positiv e 2 0 4 1 1 1
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IFN Receptor Negative 0 3 11 0
IFN Receptor Positive 2 5 2 0
HAI Score 0-3 HAI Score 4-7 HAI Score 8-12  HAI Score >12
 
Relationship between IFNα-Rc mRNA 
expression and response to IFN therapy 
HCV patients without HCC were further divided 
according to the response of therapy. Nine patients 
responded while14 patients were considered as non 
responders as HCV RNA remained positive at the 
end of the 24 weeks of treatment. A significant 





therapy and age (P= 0.004), degree of fibrosis 
(P=0.005) and the HAI score (P=0.001) Fig 7&8. 
However no association was found between the 
response and gender nor liver enzymes. The 
incidence of IFN Alpha Receptor mRNA 
expression was significantly higher in responders 
than in non-responders. Table 2 (P=0.002) 


























Non-Responder 0 0 1 1 3 9
Responder 2 0 4 1 2 0
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Non-Responder 0 1 13 0
Responder 2 7 0 0
HAI Score 0-3 HAI Score 4-7 HAI Score 8-12 HAI Score >12
  
 
Table 2: IFNα-Rc mRNA expression among the responders & non-responders 












HCV-RNA and IFNα-Rc m RNA expression 
All responders showed a negative HCV RNA result 
by the real time PCR, while non-respoders showed 
a mean 164 x 103 IU/ml ± 92 x 103 IU/ml. There 
was no correlation between the amount of HCV 
RNA after treatment in the non-responders and the 
expression of IFNα-Rc m-RNA.  
 
Discussion 
Since IFN therapy is expensive and may cause 
serious adverse effects, it would be clinically useful 
to predict the efficacy of IFN-α therapy in patients 
with HCV infection[20]. Despite recent treatment 
advances, the majority of patients with chronic 
HCV fail to respond to antiviral therapy. Although 
the genetic basis for this resistance is not clear, 
several factors are predictive to the response to 
interferon therapy. These include low amounts of 
HCV RNA and weaker activity of hepatitis, both 
predictive of favorable response to interferon. 
Other factors include the state of the pathology of 






cirrhosis and viral genotype. There is a theory that 
states that deficient expression of IFN-Receptor 
may decrease the uptake of IFN, which results in 
active viral replication [21]. 
The current study aimed to investigate the 
expression IFN-α and IFN-α Receptor genes in 
liver biopsies from patients with HCV and HCC. 
Correlation of their expression with the clinical, 
histopathological progress of the disease and the 
effectiveness of IFN therapy in HCV patients after 
a period of 6 months follow-up was done. 
Comparison between HCV patients & HCC 
patients regarding the clinical & laboratory 
findings didn’t reveal any significant differences 
except for Bilirubin and AFP levels indicating an 
obstructive element in patients which is higher with 
HCC [22]. 
Interferon Alpha mRNA expression was 
detected in 29 out of 30 patients (96.7%), only one 
patient was negative for IFN Alpha gene who had 
marked liver fibrosis & high histological activity 
index (HAI>12). Since an anti-viral state is 
established not by IFNα molecule itself but by 
proteins induced by IFNα, the binding of IFNα to 
specific receptors and intracellular signal 
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transduction after IFNα Receptor binding are 
essential steps to establish the anti-viral state. Thus, 
the response to Interferon in chronic hepatitis C 
depends on the INFα-Rc in the liver. [5,23] 
Interferon Alpha Receptor (IFNα-Rc) mRNA 
expression was found in 30% (9/30) of our patients. 
Findings confirmed that patients who expressed 
IFNα-Rc were characterized by younger age group, 
better histopathological findings (lower degree of 
fibrosis) and lower HAI score. However no 
statistical significant difference was observed 
regarding gender, other clinical and laboratory 
findings.  The difference in age may be due to the 7 
patients suffering from HCC on top of HCV, for 
whom the mean ages (56.6 ± 4) was higher than the 
group suffering from HCV alone (42.1 ± 6.6) since 
HCC is a complication of HCV. Moreover, patients 
who were suffering from HCC on top of HCV were 
all in the receptor-negative group [17, 22].  
Frequency of receptor expression was higher 
among the HCV patients and none of the patients 
who developed HCC had receptor expression. HCV 
related HCC shows stepwise regression from 
chronic hepatitis with progressive stages of fibrosis 
to cirrhosis and eventually clinically apparent 
HCC. Since all patients who developed HCC in the 
present study also had marked liver cirrhosis thus 
were showing an advanced histopathological 
picture and distortion in the liver architecture. 
Other studies had also stated that the amount of 
receptor expression is inversely proportionate to 
the pathological status of the liver [1,24] thus we 
can explain that the absence of receptor expression 
in HCC positive cases stems from this logic. One 
possibility for the decrease in the gene expression 
with histological progress may be that the gene 
expression of IFNα-Rc itself becomes suppressed 
during histological progress [25].  Another theory 
also supports the fact that continuous inflammation 
in the liver may cause some changes in protein 
synthesis [11]. Thus down regulation of IFNα gene 
expression will decrease IFNα protein production 
and hence IFNα-Rc binding, which will finally 
down regulates IFNα-Rc gene expression [10]. 
This can be attributed to the theory of suggesting 
that the lower expression of IFNα-Rc mRNA may 
be partially responsible for the poor response to 
IFNα in liver cirrhosis [4,5,10,11,23,24]. Of our 23 
HCV patients, 9 showed sustained virological 
response to IFNα. Responders to therapy were seen 
to show significantly lower mean age, better 
histopathological states (lower grades of fibrosis 
and better grade of HAI) and higher incidence of 
expression of IFNα-Rc mRNA and the differences 
were statistically significant.  
Several variables have been established as 
being associated with a greater likelihood of 
sustained virological response to interferon therapy 
[7] Morita et al., found that the presence of 
IFNαR1 or IFNαR2 mRNA predicted complete 
response to interferon treatment, with a positive 
predictive value of 100% [26]. Later in 1999 [27] 
they found that IFNα-Rc mRNA expression and the 
absence of genotype 1b were significant predictors 
of sustained biochemical and virological 
effectiveness of IFNα therapy. They added also that 
the absence of HCV genotype 1b, low titer of HCV 
RNA and expression of IFNα-Rc mRNA were 
significantly correlated with the sustained 
virological and biochemical response to interferon 
treatment. This may suggest that a poor response to 
IFN may result from deficient expression of the 
receptor. It has been explained that deficient 
expression of IFNα-Rc may reduce the uptake of 
IFNα, which results in increased viral replication 
and more severe hepatitis activity which leads to 
inflammation, increase IFN production and 
fibrosis, thus the resistance of response to therapy 
[5,25,28]. Conversely, 2 of our responders were 
IFNα-Rc negative and 2 of the non-responders 
expressed IFNα-Rc m-RNA. This can be explained 
by 1) a difference in intracellular signal 
transduction after receptor binding, 2) the presence 
of IFN sensitivity determining region (ISDR) in the 
different HCV patients because some IFN resistant 
cells may express functional receptors, 3) the 
binding affinity of the IFNα-Rc may be changed in 
non-responders despite the presence of IFNα-Rc 
molecules [8]. 
Further analysis of the amount of HCV RNA 
by real time PCR in the non-responders revealed 
that it had no association with the pretreatment 
expression of IFNα-Rc. Morita et al stated that a 
low titer of HCV RNA was not an independent 
predictor of IFN efficacy [27]. Another study found 
that IFNα-Rc m-RNA expression in 20 liver 
patients was significantly higher than 6 normal 
patients but the level did not correlate with the 
amounts of serum HCV RNA [15]. Although 
Fukada et al found that there was an inverse 
correlation between the amount of HCV RNA and 
the amount of IFNα-Rc m-RNA in both responders 
and non-responders [18], Fujiwara et al [23] stated 
that HCV-RNA level is independently associated 
with a sustained virologic response. This may be 
due to the lack of studies done on the HCV 4 
genotypes and subtypes regarding, its correlation 
with IFNα-Rc m-RNA expression. Further study 
using a large number of patients is clearly 
necessary to explain the difference [29].  
HCV RNA dependant RA polymerase (RdRp), 
like other viral RNA polymerases, has a high error 
rate, with misincorporation frequencies averaging 
about 10-4 to 10-5 per base site, due to the absence 
of a proofreading mechanism. As a result, 
mutations accumulate in newly generated HCV 
genomes. Most mutant viral particles are 
replication deficient, but some propagate 
efficiently. The fittest infectious particles are 
selected continuously on the basis of their 
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replication capacities and environmental selective 
pressures (mainly the host immune response). This 
explains why each infected individual harbors a 
pool of genetically distinct but closely related HCV 
variants referred to collectively as a quasispecies 
[8,30]. This may explain the lack of determination 
of the subtypes in our patients which need 
sequencing to differentiate between subtypes of 
genotype [4 [2]. 
 
Conclusion 
We can conclude that Interferon Alpha 
Receptor Expression decreases with the 
histological progress of the disease inspite of the 
presence of IFNα m-RNA in most of our patients 
suggesting that lower expression of the Interferon 
Alpha Receptor mRNA may be partially 
responsible for the unfavorable response to 
interferon for patients with an unfavorable 
histopathological picture and may be a predictor of 
interferon response in chronic hepatitis C. Also, 
there was no association between the IFNα-Rc m-
RNA expression and serum ALT level, and amount 
of serum HCV RNA or HCV genotype. 
It’s recommended to Quantitate the amount of 
interferon alpha receptor mRNA expression in 
order to further analyze if the quantity is related to 
the outcome. However, investigation of the amount 
of IFN-Rc mRNA in the liver is not appropriate for 
routine examination before IFN therapy in all 
patients, thus investigating IFN-Rc associated 
molecules or its expression in peripheral blood 
mononuclear cells could be performed aiming to 
avoid the invasive biopsy procedure if a correlation 
could be detected. Finally studies involving the 
relationships between interferon alpha receptor 
mRNA expression and genotype and subtype in 
Egypt might also prove useful.   
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